Royalty Pharma/RPRX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Ticker

RPRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

New York, United States

Employees

-
Website
www.royaltypharma.com

Royalty Pharma Metrics

BasicAdvanced
$12B
Market cap
13.22
P/E ratio
$1.96
EPS
0.47
Beta
$0.81
Dividend rate
3.13%
Dividend yield
$12B
0.47
$0.81
12.52
12.48
62.242
62.242
45.50%
5.10%
3.54%
12.06%
13.22
4.72
1.8
1.8
10.36
3.13%
-5.11%
136.73%
0.66%
13.69%
19.89%

What the Analysts think about Royalty Pharma

Analyst Ratings

Majority rating from 8 analysts.
Buy

Royalty Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.82% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$568M
-4.71%
Net income
$4.7M
-99.05%
Profit margin
0.82%
-99.01%

Royalty Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.20%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.84
$0.79
$1.15
$0.98
-
Expected
$0.81
$0.76
$1.01
$0.98
$0.97
Surprise
3.96%
4.50%
13.86%
-0.20%
-

Royalty Pharma News

AllArticlesVideos

Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewsWire·4 weeks ago

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

GlobeNewsWire·4 weeks ago

Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Royalty Pharma stock?

Royalty Pharma (RPRX) has a market cap of $12B as of July 03, 2024.

What is the P/E ratio for Royalty Pharma stock?

The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 13.22 as of July 03, 2024.

Does Royalty Pharma stock pay dividends?

Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $0.81 and the yield is 3.13%. Royalty Pharma has a payout ratio of 45.5% on a trailing twelve-month basis.

When is the next Royalty Pharma dividend payment date?

The next Royalty Pharma (RPRX) dividend payment date is unconfirmed.

What is the beta indicator for Royalty Pharma?

Royalty Pharma (RPRX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Royalty Pharma stock

Buy or sell Royalty Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing